Downstream effectors of oncogenic ras in multiple myeloma cells

Blood

Volumn 101, Issue 8, 2003, Pages 3126-3135

  Hu, Liping ^b   Shi, Yijiang ^b   Hsu, Jung hsin ^b   Gera, Joseph ^b   Van Ness, Brian ^b   Lichtenstein, Alan ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; CCL 779; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN KINASE B; RAPAMYCIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; DNA BINDING PROTEIN; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; FLAVONOID; HYBRID PROTEIN; I KAPPA B; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MORPHOLINE DERIVATIVE; ONCOPROTEIN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN P21; PROTEIN SERINE THREONINE KINASE; S6 KINASE; TRANSACTIVATOR PROTEIN; TRANSFERASE; TUMOR PROTEIN;

ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; GENE ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SUPPRESSOR GENE; CELL CULTURE; CELL CYCLE; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; METABOLISM; ONCOGENE RAS; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ALKYL AND ARYL TRANSFERASES; CELL CYCLE; CHROMONES; DNA-BINDING PROTEINS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FLAVONOIDS; GENES, RAS; I-KAPPA B PROTEINS; INTERLEUKIN-6; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; MORPHOLINES; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NF-KAPPA B; ONCOGENE PROTEIN P21(RAS); PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT FUSION PROTEINS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0038281345     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-08-2640     Document Type: Article

References (46)

1. Corradini P, Ladetto M, Voena C, et al. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood. 1993;81:2708-2713.
2. Paquette RL, Berenson J, Lichtenstein A, McCormick F, Koeffler HP. Oncogenes in multiple myeloma: point mutation of N-ras. Oncogene. 1990;5:1659-1663.
3. Neri A, Murphy JP, Cro L, et al. Ras oncogene mutation in multiple myeloma. J Exp Med. 1989;170:1715-1725.
4. Portier M, Moles JP, Mazars GR, et al. P53 and RAS gene mutations in multiple myeloma. Oncogene. 1992;7:2539-2543.
5. Liu P, Quam L, Billadeau D, et al. Activating mutations of N- and K-ras in multiple myeloma show distinct clinical associations: analysis of the ECOG phase III trial. Blood. 1996;88:2699-2706.
6. Corradini P, Ladetto M, Inghirami G, Boccadoro M, Pileri A. N- and K-ras oncogenes in plasma cell dyscrasias. Leuk Lymphoma. 1994;15:17-20.
7. Billadeau D, Jelinek D, Shah N, LeBien TW, Van Ness B. Introduction of an activated N-ras oncogene alters the growth characteristics of the IL-6-dependent myeloma cell line ANBL6. Cancer Res. 1995;55:3640-3646.
8. Billadeau D, Liu, P, Jelinek D, Shah N, LeBien T, Van Ness B. Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6. Cancer Res. 1997;57:2268-2275.
9. Rebollo A, Martinez CA. Ras proteins: recent advances and new functions. Blood. 1999;94:2971-2988.
10. Katz ME, McCormick F. Signal transduction from multiple ras effectors. Curr Opin Genet Dev. 1997;7:75-79.
11. Rodriguez-Viciana P, Warne PH, Vanhaesebroeck B, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature. 1994;370:527-532.
12. Mukhopadhyay NK, Price DJ, Kyriakis JM, et al. An array of insulin-activated, proline-directed serine/threonine protein kinases phosphorylate the p70 S6 kinase. J Biol Chem. 1992;267:3325-3335.
13. Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, Baldwin AS. Oncogenic Ha-Ras-induced signaling activates NF-kB transcriptional activity, which is required for cellular transformation. J Biol Chem. 1997;272:24113-24116.
14. Rowley M, Liu P, Van Ness B. Heterogeneity in the therapeutic response of genetically altered myeloma cell lines to IL-6, dexamethasone, doxorubicin and melphalan. Blood. 2000;96:3175-3180.
15. Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinaseJAKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res. 2000;60:6763-6770.
16. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kB. J Clin Invest. 2001;107:241-246.
17. Hsu J-h, Shi Y, Hu L, Fisher M, Franke TF, Lichtenstein A. Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses. Oncogene. 2002;21:1391-1400.
18. Jelinek DF, Ahmann GJ, Greipp PR, et al. Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangements: clinical implications. Cancer Res. 1993;53:5320-5327.
19. Daeipour M, Kumar G, Amaral MC, Nel AE. Recombinant IL-6 activates p42 and p44 MAP kinases in the IL-6-responsive B cell line AF-10. J Immunol. 1993;150:4743-4752.
20. Ogata A, Chauhan D, Urashima M, et al. IL-6 triggers multiple myeloma cell growth via the Ras dependent mitogen activated protein kinase cascade. J Immunol. 1997;159:2212-2220.
21. Hsu J-h, Shi Y, Krajewski S, et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood. 2001;98:2853-2855.
22. Hyun T, Yam A, Pece S, et al. Loss of PTEN expression leading to high AKT activation in human multiple myelomas. Blood. 2000;96:3560-3568.
23. Hideshima T, Nakamura N, Chauhan D,Anderson KC. Biologic sequelae of IL-6-induced PI3-K/AKT signaling in multiple myeloma. Oncogene. 2001;20:5991-6000.
24. Brunet A, Bonni A, Zigmond MJ, et al. AKT promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857-868.
25. Jefferies HBJ, Reinhard C, Kozma SC, Thomas G. Rapamycin selectively represses translation of the polypyrimidine tract mRNA family. Proc Natl Acad Sci U S A. 1994;91:4441-4445.
26. Shi Y, Hsu J-h, Hu L, Gera J, Lichtenstein A. Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to IL-6. J Biol Chem. 2002;277:15712-15720.
27. Weng Q-P, Kozlowski M, Belham C, Zhang A, Comb MJ, Avruch J. Regulation of the p70S6 kinase by phosphorylation in vivo: analysis using site specific anti-phosphopeptide antibodies. J 8iol Biol Chem. 1997;273:16621-16629.
28. Pullen N, Dennis PB, Andjelkovic M, et al. Phosphorylation and activation of p70S6K by PDK1. Science. 1998;279:707-710.
29. Isotani S, Hara K, Tokunaga C, Inoue H, Avruch J, Yonezawa K. Immunopurified mTOR phosphorylates and activates p70S6 kinase in vitro. J Biol Chem. 1999;274:34493-34498.
30. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM. RAFT1 phosphorylation of the translational regulators p70S6 kinase and 4E-BP1. Proc Natl Acad Sci U S A. 1998;95:1432-1437.
31. Mayo MW, Wang C-Y, Cogswell PC, et al. Requirement of NF-kB activation to suppress p53-independent apoptosis induced by oncogenic ras. Science. 1997;278:1812-1815.
32. Norris JL, Baldwin AS. Oncogenic Ras enhances NF-kB transciptional activity through Raf-dependent and Raf-independent mitogen activated protein kinase signaling pathways. J Biol Chem. 1999;274:13841-13846.
33. Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS. Role of NF-kB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by BCL-2. Blood. 1999;93:3044-3052.
34. Ni H, Ergin M, Huang Q, et al. Analysis of expression of NF-kB in multiple myeloma: downregulation of NF-kB induces apoptosis. Br J Haematol. 2001;115:279-286.
35. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS. NF-kB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999;19:5923-5929.
36. Suzuki N, Urano J, Tamanoi F. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc Natl Acad Sci U S A. 1998;95:15356-15361.
37. Franke TF, Yang S-I, Chan TO, et al. The protein kinase encoded by the AKT proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell. 1995;81:727-738.
38. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 1995;80:179-186.
39. Romashkova JA, Makarov SS. NF-kB is a target of AKT in anti-apoptotic PDGF signaling. Nature. 1999;401:86-90.
40. Beraud C, Henzel WJ, Baeuerle PA. Involvement of regulatory and catalytic subunits of phosphinositide 3-kinase in NF-kappaB activation. Proc Natl Acad Sci U S A. 1999;96:429-434.
41. Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin AS, Mayo MW. AKT suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kB. Mol Cell Biol. 2000;20:1626-1638.
42. Zhang FL, Kirschmeier P, Carr D, et al. Characterization of Ha-ras, N-ras, Ki-Ras4A and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J Biol Chem. 1997;272:10232-10239.
43. Du W, Liu A, Prendergast GC. Activation of the PI3′K-AKT pathway masks the pro-apoptotic effects of farnesyltransferase inhibitors. Cancer Res. 1999;59:4208-4212.
44. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A. 2001;98:10314-10319.
45. Hideshima T, Richardson P, Chauhan D, et al. The proteosome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071-3076.
46. Hideshima T, Chauhan D, Richardson P, et al. NF-kB as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639-16647.